Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris.
Gniadecki, R
Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. [electronic resource] - The British journal of dermatology Jan 2015 - 244-52 p. digital
Publication Type: Comparative Study; Journal Article
1365-2133
10.1111/bjd.13343 doi
Adalimumab
Adult
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized--therapeutic use
Biological Factors--therapeutic use
Dermatologic Agents--therapeutic use
Drug Substitution
Etanercept
Female
Humans
Immunoglobulin G--therapeutic use
Infliximab
Male
Prospective Studies
Psoriasis--drug therapy
Receptors, Tumor Necrosis Factor--therapeutic use
Treatment Outcome
Ustekinumab
Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. [electronic resource] - The British journal of dermatology Jan 2015 - 244-52 p. digital
Publication Type: Comparative Study; Journal Article
1365-2133
10.1111/bjd.13343 doi
Adalimumab
Adult
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized--therapeutic use
Biological Factors--therapeutic use
Dermatologic Agents--therapeutic use
Drug Substitution
Etanercept
Female
Humans
Immunoglobulin G--therapeutic use
Infliximab
Male
Prospective Studies
Psoriasis--drug therapy
Receptors, Tumor Necrosis Factor--therapeutic use
Treatment Outcome
Ustekinumab